Orchestra BioMed Holdings (OBIO) EBIT Margin (2022 - 2025)
Historic EBIT Margin for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to 2359.23%.
- Orchestra BioMed Holdings' EBIT Margin fell 7035100.0% to 2359.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 2669.91%, marking a year-over-year decrease of 3992200.0%. This contributed to the annual value of 2437.49% for FY2024, which is 5713300.0% down from last year.
- According to the latest figures from Q3 2025, Orchestra BioMed Holdings' EBIT Margin is 2359.23%, which was down 7035100.0% from 2311.84% recorded in Q2 2025.
- In the past 5 years, Orchestra BioMed Holdings' EBIT Margin ranged from a high of 592.15% in Q1 2022 and a low of 6591.7% during Q4 2024
- For the 4-year period, Orchestra BioMed Holdings' EBIT Margin averaged around 2298.8%, with its median value being 2166.97% (2024).
- In the last 5 years, Orchestra BioMed Holdings' EBIT Margin plummeted by -38727200bps in 2023 and then soared by 18106200bps in 2024.
- Orchestra BioMed Holdings' EBIT Margin (Quarter) stood at 891.02% in 2022, then tumbled by -435bps to 4763.74% in 2023, then crashed by -38bps to 6591.7% in 2024, then soared by 64bps to 2359.23% in 2025.
- Its EBIT Margin stands at 2359.23% for Q3 2025, versus 2311.84% for Q2 2025 and 2179.84% for Q1 2025.